Due Diligence / Market Analysis

Investors, Capital venture, Bank

Biotechs developing and commercializing drugs to treat orphan diseases where the unmet medical need is high are very attractive. Technological and scientific advances, personalized medicine,  market access regulations and rapidly moving health environment make it very difficult to anticipate the potential market of a treatment which will reach the market in few years. Very rare, sometimes no, hard data is available to make the usual market analysis. Only a customized approach can make it. Read more


With 60 cumulative years of experience in the pharmaceutical  industry, including a wide expertise of management of rare diseases and orphan drugs biotechs, we rapidly understand any specific niche medical market, to provide you with a thorough evaluation of the market potential of a treatment for a rare disease, in France and in Europe.





You need to start setting up presence in several european countries before launch of an orphan drug and look for the most cost-efficient solution. You need to manage an alliance of a biotech and a big pharma company.


We personally have experienced these situations and will provide you with a pragmatic situation analysis, strategic plans and will personally implement the operational plan. Our services can included the setting-up of the company, transition management and support to identification of key managers.








Which biotech will make it ?

The most efficient business model for a biotech ?

Affiliate Set-up / Transition Management / Alliance Management